Showing 1621-1630 of 2150 results for "".
- Lineage Cell Therapeutics Launches New Corporate Brandhttps://modernod.com/news/lineage-cell-therapeutics-launches-new-corporate-brand/2479549/Lineage Cell Therapeutics, previously BioTime, announced the effective change of its corporate name and formal launch of its new corporate brand. In connection with the launch, the company’s NYSE American ticker symbol has changed to “LCTX” and will be effective at the open of t
- Clearside Biomedical Announces Multiple Presentations Delivered at the ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-announces-multiple-presentations-delivered-at-the-asrs-annual-meeting/2479557/Clearside Biomedical announced that multiple oral presentations were delivered on Clearside’s pipeline and proprietary SCS Microinjector targeting the suprachoroidal space (SCS) at the American Society of Retinal Specialists (ASRS) Annual Meeting. “Clearside had a widespread presence at t
- Altaire Pharmaceuticals Expands Voluntary Recall Of Multiple OTC Ophthalmic Productshttps://modernod.com/news/altaire-pharmaceuticals-expands-voluntary-recall-of-multiple-otc-ophthalmic-products/2476747/Altaire Pharmaceuticals announced that it is voluntarily recalling the over-the-counter (OTC) drug products and lots, within expiry, sold by Accutome, Focus Laboratories, Grandall Distributing Co., and Prestige Brands. As a precautionary measure, Altaire is voluntarily initiating the recall due t
- FDA Accepts Allergan’s NDA for Bimatoprost SR in Patients With Glaucomahttps://modernod.com/news/fda-accepts-allergans-nda-for-bimatoprost-sustained-release-in-patients-with-open-angle-glaucoma-or-ocular-hypertension/2476739/Allergan announced that the FDA has accepted the company’s new drug application (NDA) for Bimatoprost Sustained-Release (SR) biodegradable implant for the reduction of IOP in patients with primary open-angle glaucoma or ocular hypertension. The FDA is expected to take action on the NDA by t
- Nicox Announces Completes Enrollment in NCX 470 Phase 2 Clinical Studyhttps://modernod.com/news/nicox-announces-completion-of-enrollment-in-ncx-470-phase-2-clinical-study-with-topline-results-on-track-for-early-4q-2019/2476734/Nicox SA announced that it has completed enrollment of patients in its multicenter, phase 2 clinical study evaluating NCX 470 nitric oxide (NO)-donating bimatoprost analog being tested in patients with open-angle glaucoma or ocular hypertension for its ability to lower IOP. This study is a head-t
- Aldeyra Therapeutics Phase 3 SOLACE Trial Fails to Meet Primary Endpoint in Noninfectious Anterior Uveitishttps://modernod.com/news/aldeyra-therapeutics-phase-3-solace-trial-fails-to-meet-primary-endpoint-in-noninfectious-anterior-uveitis/2476691/Aldeyra Therapeutics announced results from the noninfectious anterior uveitis SOLACE trial. Statistical significance was not achieved for the primary or secondary endpoints, due to high rates of disease resolution in vehicle-treated patients, but activity of reproxalap was consistently greater t
- Brits in the Dark Over Eye Health According to Orbis UKhttps://modernod.com/news/brits-in-the-dark-over-eye-health-according-to-orbis-uk/2476651/New research reveals that over half of Brits (53%) do not get their eyes tested every 2 years as recommended, and just over 1 in 10 (11%) can’t remember the last time they went to the optician. This is despite 45% of those surveyed listing sight as their most valuable sense. The surv
- Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meetinghttps://modernod.com/news/immunocore-to-present-new-tebentafusp-imcgp100-data-in-advanced-melanoma-at-upcoming-2019-asco-annual-meeting/2476605/Immunocore Limited, a T cell receptor (TCR) biotechnology company, will present new mechanism of action data in advanced uveal and cutaneous melanoma from the tebentafusp clinical research program at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 3, 2019. Teben
- Neuropathy May Drive Dry Eye in Migraine Patientshttps://modernod.com/news/neuropathy-may-drive-dry-eye-in-migraine-patients/2476593/Migraine patients with dry eye are more likely to have symptoms suggestive of neuropathy than dry eye patients who don’t have migraines, according to new findings, as reported by Reuters Health. The results raise the possibil
- SilkTech Biopharmaceuticals’ IND Submission Cleared by FDA for Dry Eye Drophttps://modernod.com/news/silktech-biopharmaceuticals-ind-submission-cleared-by-fda-phase-2-clinical-trial-initiated-for-patients-with-dry-eye-disease/2476469/SilkTech Biopharmaceuticals announced the company has received clearance of its investigational new drug (IND) submission with the FDA for its SDP-4 eye drop product. In addition, the company has initiated a phase 2 clinical trial for its first-in-class drug to assess the safety and efficacy of t